A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposure - Summary - MDSpire
Advertisement
A pilot study on therapeutic drug monitoring of asparaginase in Indian children with high-risk ALL: evidence for suboptimal exposure
To assess serum asparaginase activity during induction therapy in high-risk B-cell acute lymphoblastic leukemia (ALL) patients in India.
Key Findings:
Five out of nine high-risk patients completed induction therapy, highlighting the challenges in treatment adherence.
Three patients died from treatment-related complications, underscoring the risks associated with inadequate monitoring.
All evaluable patients had subtherapeutic trough asparaginase activity (<0.5 IU/mL), indicating a critical gap in therapeutic efficacy.
Peak asparaginase levels showed significant interpatient variability (0.52–1.97 IU/mL), suggesting the need for individualized dosing.
Higher enzyme activity correlated with various biochemical toxicities, emphasizing the importance of monitoring to mitigate risks.
Interpretation:
The study indicates consistently subtherapeutic trough levels of asparaginase in high-risk pediatric ALL patients, suggesting inadequate drug exposure that could compromise treatment efficacy and safety, necessitating therapeutic drug monitoring.
Limitations:
Small sample size limits generalizability, making it difficult to draw broad conclusions.
Lack of control group for comparison restricts the ability to assess the true impact of asparaginase monitoring.
Resource constraints may affect broader implementation of therapeutic drug monitoring, highlighting a significant barrier to improving patient outcomes.
Conclusion:
The findings underscore the urgent need for therapeutic drug monitoring in optimizing asparaginase dosing and minimizing toxicity in resource-limited settings, warranting larger studies to validate results and inform future treatment protocols.
